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Background: The most common cystic ﬁbrosis-associated mutation, the deletion of phenylalanine 508 (F508del), results in channels with poor
membrane expression and impaired function. VX-770, a clinically approved drug for treatment of CF patients carrying the G551D mutation, and
VX-809, a corrector shown in vitro to increase membrane expression of mutant channels, are currently undergoing clinical trials, but functional
data at the molecular level is still lacking.
Methods: The effect of VX-770 and VX-809 on the multiple functional defects of F508del-CFTR was assessed via excised inside-out patch-clamp
experiments.
Results: VX-770 completely restores the low opening-rate of F508del-CFTR, with smaller open-time increase, in temperature-corrected and VX-809-
treated channels. The shorter locked-open time of hydrolysis-deﬁcient F508del-CFTR is also prolonged by VX-770. VX-809 does not improve channel
function by itself as previously reported.
Conclusions: The results from these studies can be interpreted as an equilibrium shift toward the open-channel conformation of F508del-CFTR channels.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; VX-770; VX-809; Electrophysiology; Pharmacology1. Introduction
The Cystic Fibrosis Transmembrane Conductance Regu-
lator (CFTR) is a chloride channel that plays a critical role in
maintaining fluid and electrolyte balance across many
epithelium-lining tissues [1]. Mutations in CFTR that decrease
the channel expression and function result in the lethal hereditary
disease cystic fibrosis (CF) [1,2].
The CFTR channel is composed of two transmembrane
domains (TMDs), two nucleotide-binding domains (NBDs), and
a regulatory domain (RD). Phosphorylation of the RD by PKA⁎ Corresponding author at: Dalton Cardiovascular Research Center, 134 Research
Park Dr., Columbia, MO 65211, USA. Tel.: +1 573 884 9474; fax: +1 573 884
4232.
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. A(protein kinase A) is required for the channel to function. ATP
binding to the NBDs leads to the formation of an NBD dimer
with the ATP trapped at the dimer interface triggering channel
opening. Hydrolysis of the ATP bound at the NBD2 site leads to
the partial separation of the dimer and channel closure (for a
comprehensive review see Ref. [3]). This partial NBD dimer,
lasting for tens of seconds, allows another ATP molecule to bind
to NBD2 and initiate a new gating cycle. CFTR channels can
open also in the absence of ATP, although very infrequently [4].
Deletion of phenylalanine 508 (F508del) is the most common
CF-associated mutation [5]. F508del-CFTR channels exhibit
defective protein production and processing [6,7], defective
function [7–10] and reduced cell membrane lifetime [11,12].
Recently we demonstrated several functional defects for F508del
channels [10,13]: the open probability (Po) of F508del-CFTR
is ~15 times lower than that of wild-type (WT) channels [10],ll rights reserved.
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[10]; F508del-CFTR channels also have shortened locked-
open time, and ligand-exchange time at the NBD1 site
(non-hydrolytic) suggesting that the mutation may destabilize
the full and partial NBD dimer states [13].
ATP analogs are unsuitable for therapeutic use, but small-
molecules can be used for targeted treatment in CF. VX-770
(Ivacaftor) is the first CFTR potentiator approved by the Food
and Drug Administration (USA), the European Medicines
Agency, Health Canada and the Therapeutic Goods Administra-
tion in Australia, for clinical application to patients 6-years and
older carrying the G551D mutation which targets the molecular
defect of the protein [14,15]. Bompadre et al. [4] demonstrated
that the G551D mutation abolishes the ATP-dependent gating of
these channels, exhibiting only ATP-independent openings.
Not surprisingly, VX-770 potentiates G551D-CFTR activity by
increasing the ATP-independent opening-rate and the open time
[16,17]. VX-770 also increases the ATP-dependent activity of
WT-CFTR channels [17], as well as other CFTR mutants only
when present at the cell surface, including F508del [14,18,19].
F508del-CFTR channels have primarily a folding and process-
ing defect and considerable effort is centered in finding compounds
(correctors) to improve the trafficking problem. Recently a new
compound, VX-809, emerged as a plausible corrector specifically
addressing the underlying processing defect in F508del-CFTR,
allowing quantifiable amounts of CFTR to traffic to the cell surface
[20]. A study of VX-809 on patients homozygous for the F508del
mutation did not show improvements in clinical outcomes [21]
suggesting that even if VX-809 corrected channel trafficking,
their function may still be defective. A new clinical study
combining both VX-770 and VX-809 is currently underway
(ClinicalTrials.gov identifier NCT0122521). Interestingly, de-
tailed functional data at the molecular level demonstrating the
effect of this drug combination is still lacking.
In this study we tested the effect of VX-770 on the different
functional defects associated with F508del channels. We found
that VX-770 increases the activity of the mutant channels
expressed in Chinese hamster ovary (CHO) cells as well as
human epithelial CFPAC-1 cells mainly by increasing the ATP-
dependent opening-rate of the channels, similar to the effect
produced by P-dATP [10]. VX-770 also reduces the hydrolytic
and non-hydrolytic closing-rates. Contrary to what has been
reported [20], F508del channels treated with corrector VX-809 did
not show improved function, having similar activity to that of low
temperature-corrected channels. On the other hand, channels
treated with VX-809 and VX-770 resulted in increased channel
expression at the membrane and maximally potentiated activity,
indicating that the combination of both compounds could be a
viable treatment for people bearing the F508del mutation, provided
the level of correction induced by VX-809 is sufficient.
2. Results
2.1. Effect of VX-770 on the low opening-rate of F508del-CFTR
We studied the effect of the potentiator VX-770 in F508del-
CFTR channels expressed in CHO and human CFPAC-1 cells viapatch-clamp experiments in the inside-out mode. We compared it
to the effect of the high-affinity ATP-analog P-dATP, which we
showed tomaximally potentiate F508del-CFTR currents since the
addition of genistein, a well-known CFTR potentiator [22], failed
to further increase the current induced by P-dATP [10]. The cells
were incubated at 27 °C for 48 h to allow for the correction of the
trafficking defect of these channels.
After the channels were activated with 2 mM ATP + 20 U/ml
PKA, the addition of 200 nM VX-770, a saturating concentration
[17], resulted in a 13 ± 3 fold increase of the steady-state
ATP-elicited current (n = 8). To determine whether the increase
in the current was due to an increase in the open time or the
opening-rate of the channels, we used patches containing no more
than 4 channels to perform single-channel kinetic analysis.
Fig. 1A shows that F508del-CFTR channels exposed to saturating
concentrations of ATP (2 mM) exhibited infrequent openings,
with Po = 0.022 ± 0.005 (n = 11). The addition of 200 nM
VX-770 increased the Po of F508del-CFTR to 0.45 ± 0.03,
mainly by increasing the opening-rate with smaller increase in the
open time (n = 23, Fig. 1B). The observed potentiation effect by
VX-770 was very similar to the one reported for the high-affinity
ATP analog P-dATP [10]. The channels were also exposed to
10 μM P-dATP, in conjunction with VX-770 (Fig. 1A), in order
to determine if it could further potentiate the channel activity.
P-dATP further increased the ATP + VX-770 induced current
by 35 ± 5% (n = 8), indicating that 200 nM VX-770 almost
completely rectified the low Po of temperature-corrected F508del-
CFTR channels.
Experiments carried out with human CFPAC-1 cells express-
ing recombinant F508del-CFTR show that 200 nM VX-770
increased the Po of F508del-CFTR to 0.38 ± 0.10 (n = 5), a
value comparable to that of F508del-CFTR channels expressed in
CHO cells.
2.2. Effect of VX-770 on F508del-CFTR channels corrected
with VX-809
The corrector VX-809 has been shown in vitro to increase
the amount of CFTR proteins present at the cell membrane by
34% [20,23], as well as to improve the Po of the channels [20].
First we examined the level of potentiation induced by VX-809
on F508del-CFTR channels expressed in CHO cells and
CFPAC-1 cells. Fig. 2A–B shows that 10 μM P-dATP increased
the current by 15.4 ± 1.5 fold, compared to 2 mM ATP, in CHO
cells (n = 6) and 9.6 ± 1.7 fold in CFPAC-1 cells (n = 5),
indicating that the Po of VX-809-treated F508del channels is still
very low. The low Po found for VX-809-treated F508del-CFTR
(Po = 0.036 ± 0.006, n = 14) does not agree with previous
findings (Po = 0.39 ± 0.04, [20]). The reason for the discrepancy
could be due to different experimental conditions or the different
cell lines. Interestingly, the clinical trial of this compound did not
show improvement in CFTR function [21].
Next, we tested the effect of VX-770 on F508del channels
treated with VX-809 and found similar results to those of
temperature-corrected channels (Fig. 2C–D). Table 1 summarizes
the kinetic parameters for F508del-CFTR channels expressed in
CHO and CFPAC-1 cells treated with 3 μM VX-809 in the
Fig. 1. Effect of 200 nM VX-770 on temperature-corrected F508del-CFTR channels expressed in CHO cells. A. Representative recordings of F508del-CFTR current
activity in an excised inside-out membrane patch in the presence of 2 mM ATP, 2 mMATP + 200 nM VX-770 and 10 μM P-dATP + 200 nM VX770. B. Summary
of the kinetic parameters: open probability (Po), open time (To) and opening-rate (rco) of F508del-CFTR channels in the presence of 2 mM ATP and 2 mM
ATP + 200 nM VX-770 (n = 23). WT data are included for comparison. Data are presented as means ± SEM. Here and below the dashed line represent the base line.
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viability of this drug combination as a therapeutic option will
ultimately depend on the effectiveness of correction induced by
VX-809.
2.3. Effect of VX-770 on the locked-open state of F508del-CFTR
We have previously shown that the F508del mutation
decreases the locked-open time of hydrolysis-deficient channels
[13], suggesting perhaps a destabilization of the NBD dimer
conformation.
Here we gauge the effect of VX-770 on this functional defect
of F508del-CFTR. We introduced the E1371S mutation, which
abolishes ATPase activity [24], in WT and F508del-CFTRchannels and expressed them in CHO cells. The duration of the
locked-open time of the channels is calculated from the time-
constants of F508del/E1371S and E1371S-CFTR current relax-
ations upon ATP withdrawal. As shown in Fig. 3A–B, 200 nM
VX-770 prolonged the locked-open times of hydrolysis-deficient
channels with and without the F508del mutation. The relaxation
time constant increases about 60% for both F508del/E1371S and
E1371S-CFTR, suggesting that the effect may not be specific to
the mutant channel.
The high-affinity ATP analog P-ATP has been shown to
stabilize the open time of WT-CFTR [25] and F508del-CFTR
[13] channels by binding to NBD1. When used in conjunction
with 200 nM VX-770, the locked open time of F508del/E1371S
channels can be further increased to 108 ± 12 s (n = 14), a value
Fig. 2. Representative current traces of F508del-CFTR channels corrected with
3 μM VX-809. The characteristic small current elicited by 2 mM ATP can be
greatly increased by using 10 μM P-dATP indicating that the corrector has little
effect on the functional defect of the channel. A. F508del-CFTR channels
expressed in CHO cells; B. F508del-CFTR channels expressed in CFPAC-1
cells; C. F508del-CFTR channels expressed in CFPAC-1 cells in the presence
of 200 nM VX-770 and 200 nM VX-770 + 10 μM P-dATP. D. Summary of
current fold increase induced by 10 μM P-dATP and by 200 nM VX-770 in
both cell lines.
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VX-770, indicating that VX-770 alone is not sufficient to fully
restore the stability of the open-channel conformation of F508del
channels when hydrolysis is abolished.
2.4. Effect of VX-770 on the resident time of ATP at NBD1
Another functional defect of F508del-CFTR channels we
recently unveiled is the shorter resident-time of ATP bound atTable 1
Kinetic parameters for VX-809 or low temperature corrected F508del-CFTR channel
cell lines. Channels were later exposed to 10 μM P-dATP to accurately determine t
VX-809
ATP
CHO cells To, ms 623 ± 120
rco, s
−1 0.05 ± 0.01
Po 0.036 ± 0.006
CFPAC-1 cells To, ms 614 ± 217
rco, s
−1 0.06 ± 0.01
Po 0.036 ± 0.009NBD1 [13]. For WT channels ATP remains bound at this site
for tens of seconds [26]. On the other hand for F508del-CFTR
channels this time is reduced to 3 s [13], suggesting a desta-
bilization of the partial dimer configuration.
We performed a ligand-exchange protocol (ATP/P-ATP) in the
presence of VX-770 to determine whether the lifetime of the
partial dimer state in F508del is restored. In the absence of
VX-770, when the ligand is switched fromATP to P-ATP, there is
a fast current raising-phase, which represents the ATP/P-ATP
exchange in the NBD2 site, followed by a slow current rising-
phase representing the ATP/P-ATP exchange in the NBD1 site
[13]. The tightness of ligand binding at the NBD1 site can be
examined quantitatively by measuring the time constant of
the slow phase upon ligand-exchange. When the protocol is
performed in the presence of 200 nM VX-770 (Fig. 4A), the
ATP/P-ATP switch resulted in a small current increase (40 ±
10%; n = 8) that could be fitted by a single exponential function
with time constant 2.5 ± 0.5 s (n = 8), with no evident fast
rising-phase. This value is similar to the slow-phase time constant
(ATP/P-ATP exchange in NBD1) for F508del-CFTR channels in
the absence of VX-770 [13].
Kinetic analysis indicates that the main effect of P-ATP is to
further increase the open time (55 ± 10%) with a smaller
increase in the opening-rate (24 ± 8%) (Fig. 4B). Thus if the
current increase in Fig. 4A is duemainly to the increase in the open
time (P-ATP binding to NBD1 site [25]), then the ATP/P-ATP
exchange at the NBD1 site occurs as fast as in F508del channels
not exposed to VX-770. The lack of a fast rising-phase (ATP/
P-ATP exchange at NBD2) in the ligand-exchange experiments
may be due to the large increase in the opening-rate already caused
by VX-770. The faster ligand-exchange at NBD1 (partial dimer
configuration) does not seem to be affected by VX-770, although
the small current increase elicited by P-ATP warrants caution
when interpreting the data.
3. Discussion
In this study we examined, at the molecular level, the effects
of the clinically-approved drug VX-770 (Ivacaftor) on several
functional defects of F508del-CFTR channels either treated with
corrector VX-809, a combination currently under clinical trial,
or low temperature-corrected. In both cases VX-770 increases
the Po of F508del channels to WT levels by two different
mechanisms: increasing the ATP-dependent opening-rate and
slowing the closing-rate of the channels. Contrary to what wass in the presence of 2 mM ATP and 2 mM ATP + 200 nM VX-770 for different
he number of channels present in the patch (n = 5–23).
Low-temperature
ATP + VX-770 ATP ATP + VX-770
2153 ± 576 579 ± 104 1990 ± 258
0.61 ± 0.12 0.049 ± 0.015 0.97 ± 0.20
0.554 ± 0.088 0.022 ± 0.005 0.45 ± 0.03
2260 ± 406 508 ± 101 2484 ± 306
0.25 ± 0.03 0.04 ± 0.01 0.34 ± 0.11
0.35 ± 0.04 0.021 ± 0.004 0.38 ± 0.10
Fig. 3. Effect of VX-770 on the locked-open time of F508del-CFTR channels. Representative traces for F508del/E1371S (A.) and E1371S (B.) current decay and
their exponential fits (red lines) after application of 2 mM ATP + 200 nM VX-770. Fits of current relaxation in the absence of VX-770 are shown for comparison
(blue lines). C F508del/E1371S-CFTR current relaxation after 10 μM P-ATP + 200 nM VX-770 withdrawal and its exponential fit (green line) shown in comparison
with representative fit for the relaxation after ATP + VX-770 (red line). D. summary of the effect of 200 nM VX-770 on the open time of F508del/E1371S and
E1371S CFTR (n = 9–15). CFTR channels were expressed in CHO cells incubated at 27 °C.
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F508del-CFTR function induced by VX-809.
The F508del mutation causes defective protein folding and
assembly resulting in very poor expression at the cell membrane
[6]. Partial correction of this trafficking defect is achieved in vitro
by incubating the cells at 27 °C [7], or by small-molecule
“correctors”, like the recently discovered compound VX-809 [20].
In both cases, the channels that reach the cell membrane have
defective function. The Po is extremely low, around 0.03, 15 times
lower than that of WT channels, due to a greatly diminished
opening-rate [10]. Here we show that this low Po can be corrected
by VX-770, mainly by greatly increasing the opening-rate and
increasing the open time of the channels. We also show that the
effect of VX-770 on F508del-CFTRmimics the effect of P-dATP,
which we have demonstrated to maximally potentiate the channel
activity [10].
We also studied the effect of VX-770 on the other functional
defects associated with F508del-CFTR channels, namely the
shorter locked-open time and the faster ligand-exchange time
in NBD1. The shorter locked-open time of F508del-CFTR
channels can be interpreted as a destabilization of the full dimer
configuration. The addition of VX-770 slows the non-hydrolytic
closure, and a combination of VX-770 with the ATP-analog
P-ATP can further increase this locked-open time, suggesting that
both compounds may act differently to stabilize the open channel
conformation. On the other hand, the faster ligand-exchange time
at NBD1 (partial dimer configuration) does not seem to be
affected by VX-770.
The mechanism of action of VX-770 is not fully understood.
VX-770 has shown some efficacy in improving the lung-function
of CF patients carrying the G551Dmutation. In vitro, it potentiates
the activity of G551D-CFTR channels, a mutant that does notrespond to ATP, by approximately 10 fold [14]. VX-770 also
potentiatesWT-CFTR activity by increasing the open time and the
opening-rate of the channels in an ATP-dependent manner, as well
as the ATP-independent activity of the channels [17]. Several other
CFTR mutants exhibiting gating defects are potentiated by
VX-770 [18,19].
Our data show that the main effect of VX-770 on F508del-
CFTR is to increase dramatically the ATP-dependent opening-
rate of the channels. Based on recently proposed kinetic models
[27], we can interpret the increase in the opening-rate as a
destabilization of the closed-state with two bound ATP molecules,
shifting the equilibrium toward the open-state. Further evidence
that this open-state is favored is provided by the decreased
hydrolytic and non-hydrolytic closing rates.
The open time of CFTR channels is controlled by hydrolysis
and can be modulated by the “tightness” of nucleotide binding at
NBD1 (demonstrated for ATP-analogs or mutations) [25,28]. A
new mechanism has been proposed in which a new ATP molecule
can bind to NBD2 after being vacated through hydrolysis, before
the channel closes [27]. Facilitating this open-to-open transition by
stabilizing the open-state with just one ATP bound at NBD1 leads
to a lengthening of the open time of the channels [17]. This
mechanism could explain the 3-fold increase in the open time of
ΔF508 channels, since neither hydrolysis nor tighter nucleotide
binding to NBD1 is likely responsible for this effect.
Whether VX-770 shifts the equilibrium toward the open-state
of the channel by affecting the NBD dimeric conformation or the
open conformation of the pore is not known at this point.
Certainly more studies are needed to fully characterize the
mechanism of action of this important compound.
In summary, this study provides the first description, at the
molecular level, of the combined effect of VX-770 and VX-809,
Fig. 4. Effect of VX-770 on the destabilization of the partial dimer configuration
induced by the F508del mutation. A. Ligand exchange experiment for temperature-
corrected F508del-CFTR channels expressed in CHO cells in the presence of
200 nM VX-770. Upon ATP/P-ATP exchange there is a modest increase in the
current with a time course that can be fitted with a single-exponential function with
time constant 2.5 ± 0.5 s (n = 8). B. Effect of 30 μM P-ATP on F508del-CFTR
currents in the presence of 200 nM VX-770. The main effect of P-ATP is to further
increase the open time of the channels (n = 8).
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function. We show that VX-770 is perhaps the most potent
drug available for VX-809-corrected F508del-CFTR channels.
Whether the amount of correction provided by VX-809 is enough
to be clinically relevant for patients with CF is still an open
question that will likely be answered by ongoing medical studies.4. Methods
CHO and CFPAC-1 cells were grown at 37 °C and 5% CO2
in Dulbecco's modified Eagle's medium and Iscove's modified
Dulbecco's medium respectively, supplemented with 10% fetal
bovine serum. CHO cells were transfected using Polyfect
(Qiagen) and CFPAC-1 cells were infected with adenoviruses
expressing ΔF508-CFTR as previously reported [10,13].
Although the CFPAC-1 cell line was established from a
pancreatic adenocarcinoma derived from a patient with CF
[29], the cells do not respond to cAMP stimulation [30].F508del-expressing cells were incubated at 27 °C for 48 h or
were treated with 3 μMVX-809 added to the culture medium and
incubated at 37 °C for 24–48 h before patch-clamp experiments.
Membrane currents were recorded at room-temperature
(22–24 °C) with an EPC10 amplifier (HEKA) as previously
reported [13]. The membrane potential was held at −60 mV and
the inward current was inverted for clear data presentation.
Igor-Pro (WaveMetrics) was used to calculate steady-state
mean currents and current relaxation time constants. Current
traces containing fewer than five channel-opening levels were
selected for single-channel kinetic analysis as described previ-
ously [10]. All averaged data are presented as mean ± SEM; n
represents the number of patches from different cells.
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